Rx Reimport Ban Should Be Lifted, Supply Controls Allowed, Cato Institute Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug manufacturers should be free to pursue market segmentation through their global pricing decisions, a report by the Cato Institute states. The think tank endorsed Rx import legislation, while advocating the use of contractual mechanisms to segment markets.